Blog

Narjust Florez: Dr. Julia Rotow discussed the role of IO in patients with target mutations

Photo taken from Narjust Florez/X

Apr 22, 2024, 10:32

Narjust Florez: Dr. Julia Rotow discussed the role of IO in patients with target mutations

Narjust Florez shared a post on X:

“IO and target therapy?

Dr. Julia Rotow discussed the role of IO in patients with target mutations: toxicity, potential combinations, and when patients with target mutations can receive IO.”

Source: Narjust Florez/X

Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. She received the 2020 Rising Star award by the LEAD National Conference for women in hematology and oncology. In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.

About OncoDaily

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.